Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds
US-2018072756-A1 · Mar 15, 2018 · US
Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US11230554B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11230554-B2 |
| Application number | US-201916360958-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 21, 2019 |
| Priority date | Jul 30, 2003 |
| Publication date | Jan 25, 2022 |
| Grant date | Jan 25, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lupus erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating an autoimmune disease or symptom thereof in a patient in need of such treatment, the method comprising administering to the patient a therapeutically effective amount of N4-(2,2-Dimethyl-3-oxo-4H-5-pyrid[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine. 2. The method of claim 1 wherein the disease is a Type II, Type III and/or Type IV nonanaphylactic hypersensitivity reaction. 3. The method of claim 1 wherein the disease is mediated, at least in part, by activation of the FcγR signaling cascade in monocyte cells. 4. The method of claim 1 wherein the disease is selected from the group consisting of Hashimoto's thyroiditis, autoimmune hemolytic anemia, autoimmune atrophic gastritis of pernicious anemia, autoimmune encephalomyelitis, autoimmune orchitis, Goodpasture's disease, autoimmune thrombocytopenia, sympathetic ophthalmia, myasthenia gravis, Graves' disease, primary biliary cirrhosis, chronic aggressive hepatitis, ulcerative colitis and membranous glomerulopathy. 5. The method of claim 1 wherein the disease is selected from the group consisting of systemic lupus erythematosis, Sjogren's syndrome, Reiter's syndrome, polymyositis-dermatomyositis, systemic sclerosis, polyarteritis nodosa, multiple sclerosis and bullous pemphigoid. 6. The method of claim 1 wherein the disease is autoimmune hemolytic anemia. 7. The method of claim 1 wherein the disease is autoimmune thrombocytopenia.
Assignees
Inventors
Classifications
in which the condensed system contains two hetero rings · CPC title
containing three or more hetero rings · CPC title
containing three or more hetero rings · CPC title
ortho- or peri-condensed with carbocyclic ring systems · CPC title
Peri-condensed systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11230554B2 cover?
- The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lupus erythe…
- Who is the assignee on this patent?
- Rigel Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D413/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).